article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. But over time, trends in what evidence is most available and therefore most used, change.

Safety 111
article thumbnail

How can evidence-based medicine (EBM) methodology support drug withdrawals?

European Pharmaceutical Review

Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators. Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. Six products were withdrawn or revoked for safety reasons during the study period.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Use of Big Data in Pharmaceutical Marketing: Opportunities and Challenges

Pharma Marketing Network

Additionally, by analyzing data from completed clinical trials, companies can gain insights into the safety and effectiveness of their products, which can inform the development of new drugs. 1 (2016) 3. The post The Use of Big Data in Pharmaceutical Marketing: Opportunities and Challenges appeared first on Pharma Marketing Network.

article thumbnail

The Use of Big Data in Pharmaceutical Marketing: Opportunities and Challenges

Pharma Marketing Network

Additionally, by analyzing data from completed clinical trials, companies can gain insights into the safety and effectiveness of their products, which can inform the development of new drugs. 1 (2016) 3. The post The Use of Big Data in Pharmaceutical Marketing: Opportunities and Challenges appeared first on Pharma Marketing Network.

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

The drug is recognised in several international clinical guidelines for use as monotherapy or combination treatment regimens for advanced gastric cancer, including the European Society for Medical Oncology (ESMO), 2 the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). 5): V38-V49. Oncotarget.

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

Baptist Health System (BHS), a clinically integrated network of five hospitals in San Antonio, Texas, entered the Medicare Acute Care Episodes (ACE) program in 2009 and implemented behavioral economics to incentivize clinician performance. Healthcare (2016), [link] [2] Parikh, R. Manuscript in Preparation]. [3]

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

The pharmaceutical industry of 2022 is very different from the space that we all knew in 2012, 2016, or even 2020. More convenience and safety? Fewer Networking & Industry Trade Show Events. The Traditional Pharma Model Isn’t Working – It’s Time to Evolve! August 23, 2022. dstansberry@costellocreativegroup.com.

Pharma 52